Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial.
Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL; Rare Tumor Initiative Team.
Cabanillas ME, et al.
JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4729. Online ahead of print.
JAMA Oncol. 2024.
PMID: 39446377